SEC Form 4 · accession 0001209191-18-021060
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kaye I Foster-Cheek
Director
Period of report
Mar 19, 2018
Accepted (ET)
Mar 21, 2018 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Mar 19, 2018 | M | 6,800 | $47.33 | A | 9,000 | D | |
| Common stockF3 | Mar 19, 2018 | S | 6,800 | $81.97 | D | 2,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F4 | $47.33 | Mar 19, 2018 | M | 6,800 | D | — | Jun 20, 2026 | Common stock | 6,800 | 0 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017.